- Home
- VRAX vs DOMH Comparison
VRAX vs DOMH Comparison
Compare VRAX & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- DOMH
- Stock Information
- Founded
- VRAX 2013
- DOMH 1967
- Country
- VRAX United Kingdom
- DOMH United States
- Employees
- VRAX N/A
- DOMH N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- DOMH Health Care
- Exchange
- VRAX Nasdaq
- DOMH Nasdaq
- Market Cap
- VRAX 4.7M
- DOMH 83.3M
- IPO Year
- VRAX 2022
- DOMH N/A
- Fundamental
- Price
- VRAX $0.91
- DOMH $4.95
- Analyst Decision
- VRAX Strong Buy
- DOMH
- Analyst Count
- VRAX 1
- DOMH 0
- Target Price
- VRAX $3.00
- DOMH N/A
- AVG Volume (30 Days)
- VRAX 46.8K
- DOMH 276.9K
- Earning Date
- VRAX 02-05-2025
- DOMH 08-07-2025
- Dividend Yield
- VRAX N/A
- DOMH 6.41%
- EPS Growth
- VRAX N/A
- DOMH N/A
- EPS
- VRAX N/A
- DOMH N/A
- Revenue
- VRAX $6,331.00
- DOMH $24,891,000.00
- Revenue This Year
- VRAX $217,274.83
- DOMH N/A
- Revenue Next Year
- VRAX N/A
- DOMH N/A
- P/E Ratio
- VRAX N/A
- DOMH N/A
- Revenue Growth
- VRAX N/A
- DOMH 630.80
- 52 Week Low
- VRAX $0.74
- DOMH $0.83
- 52 Week High
- VRAX $9.00
- DOMH $13.58
- Technical
- Relative Strength Index (RSI)
- VRAX 50.78
- DOMH 44.76
- Support Level
- VRAX $0.84
- DOMH $4.94
- Resistance Level
- VRAX $0.99
- DOMH $5.21
- Average True Range (ATR)
- VRAX 0.07
- DOMH 0.40
- MACD
- VRAX 0.02
- DOMH -0.08
- Stochastic Oscillator
- VRAX 60.20
- DOMH 0.64
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.